1. Home
  2. NGS vs TRDA Comparison

NGS vs TRDA Comparison

Compare NGS & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Natural Gas Services Group Inc.

NGS

Natural Gas Services Group Inc.

N/A

Current Price

$37.29

Market Cap

471.6M

Sector

Energy

ML Signal

N/A

TRDA

Entrada Therapeutics Inc.

N/A

Current Price

$11.04

Market Cap

404.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NGS
TRDA
Founded
1998
2016
Country
US
US
Employees
N/A
N/A
Industry
Oilfield Services/Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
471.6M
404.4M
IPO Year
2006
2021

Fundamental Metrics

Financial Performance
Metric
NGS
TRDA
Price
$37.29
$11.04
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
$39.00
$20.00
AVG Volume (30 Days)
132.1K
207.2K
Earning Date
01-01-0001
04-06-2026
Dividend Yield
1.17%
N/A
EPS Growth
260.53
940.00
EPS
1.25
N/A
Revenue
$156,742,000.00
$210,782,000.00
Revenue This Year
$9.83
N/A
Revenue Next Year
$14.49
$21.02
P/E Ratio
$29.98
N/A
Revenue Growth
29.36
63.38
52 Week Low
$16.73
$4.93
52 Week High
$38.37
$13.82

Technical Indicators

Market Signals
Indicator
NGS
TRDA
Relative Strength Index (RSI) 67.26 50.43
Support Level $35.51 $10.48
Resistance Level $38.37 $11.43
Average True Range (ATR) 1.18 0.74
MACD 0.17 -0.04
Stochastic Oscillator 83.07 48.47

Price Performance

Historical Comparison
NGS
TRDA

About NGS Natural Gas Services Group Inc.

Natural Gas Services Group Inc provides natural gas compression equipment and services to the energy industry. The company manufactures, fabricates, rents, sells, and maintains natural gas compressors and flare systems for oil and natural gas production and plant facilities. Its operating units include Rental, Sales, and Aftermarket services. The company generates the majority of its revenue by renting out low- to medium-horsepower compression equipment to natural gas production companies in unconventional oil and gas regions of the United States.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: